
Richard E Gilbert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11455510/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Late intervention in the remnant kidney model attenuates proteinuria but not glomerular filtration rate decline. Nephrology, 2021, 26, 270-279.	1.6	4
2	Impact of sodium glucose linked cotransporterâ€2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus. Physiological Reports, 2021, 9, e14890.	1.7	13
3	Empagliflozin Reduces Myocardial Extracellular Volume in Patients WithÂType 2 Diabetes and CoronaryÂArtery Disease. JACC: Cardiovascular Imaging, 2021, 14, 1164-1173.	5.3	51
4	Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 200.	6.8	10
5	Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2020, 141, 704-707.	1.6	225
6	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. Nephrology Dialysis Transplantation, 2020, 35, 895-897.	0.7	22
7	Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. Journal of the American Society of Echocardiography, 2020, 33, 644-646.	2.8	18
8	Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. Cardiovascular Diabetology, 2020, 19, 13.	6.8	42
9	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2019, 140, 1693-1702.	1.6	371
10	Impaired <scp>SIRT</scp> 1 activity leads to diminution in glomerular endowment without accelerating ageâ€associated <scp>GFR</scp> decline. Physiological Reports, 2019, 7, e14044.	1.7	4
11	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	1.7	474
12	Treatment of Diabetes in People With Heart Failure. Canadian Journal of Diabetes, 2018, 42, S196-S200.	0.8	24
13	Treatment of Hypertension. Canadian Journal of Diabetes, 2018, 42, S186-S189.	0.8	15
14	Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization. Circulation, 2018, 137, 88-90.	1.6	30
15	Reversing CXCL10 Deficiency Ameliorates Kidney Disease in Diabetic Mice. American Journal of Pathology, 2018, 188, 2763-2773.	3.8	14
16	Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation. Cardiovascular Research, 2018, 114, 1629-1641.	3.8	63
17	Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction. Cardiovascular Diabetology, 2018, 17, 99.	6.8	32
18	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology, 2017, 33, 557-576.	1.7	269

#	Article	IF	CITATIONS
19	Proximal Tubulopathy: Prime Mover and Key Therapeutic Target in Diabetic Kidney Disease. Diabetes, 2017, 66, 791-800.	0.6	231
20	Sirtuin 1 Activation Reduces Transforming Growth Factor-β1–Induced Fibrogenesis and Affords Organ Protection in a Model of Progressive, Experimental Kidney and Associated Cardiac Disease. American Journal of Pathology, 2017, 187, 80-90.	3.8	42
21	Progenitor cell secretory products exert additive renoprotective effects when combined with ace inhibitors in experimental CKD. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2016, 17, 147032031666843.	1.7	2
22	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	1.7	400
23	Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease. PLoS ONE, 2016, 11, e0144640.	2.5	47
24	Application of Modular Therapy for Renoprotection in Experimental Chronic Kidney Disease. Tissue Engineering - Part A, 2015, 21, 1963-1972.	3.1	1
25	Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet, The, 2015, 385, 2107-2117.	13.7	240
26	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	1.7	431
27	Heart failure: fatal, forgotten, and frequent in type 1 diabetes too. Lancet Diabetes and Endocrinology,the, 2015, 3, 832-834.	11.4	3
28	SDF-1/CXCR4 Signaling Preserves Microvascular Integrity and Renal Function in Chronic Kidney Disease. PLoS ONE, 2014, 9, e92227.	2.5	39
29	Sodium–glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?. Kidney International, 2014, 86, 693-700.	5.2	93
30	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and TreatmentÂof Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	1.7	221
31	Impaired cardiac anti-oxidant activity in diabetes: human and correlative experimental studies. Acta Diabetologica, 2014, 51, 771-782.	2.5	11
32	The Endothelium in Diabetic Nephropathy. Current Atherosclerosis Reports, 2014, 16, 410.	4.8	25
33	A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction. International Journal of Cardiology, 2013, 168, 1174-1185.	1.7	11
34	The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2013, 29, 528-542.	1.7	163
35	Role of the eNOS-NO System in Regulating the Antiproteinuric Effects of VEGF Receptor 2 Inhibition in Diabetes. BioMed Research International, 2013, 2013, 1-8.	1.9	12
36	Early-Outgrowth Bone Marrow Cells Attenuate Renal Injury and Dysfunction via an Antioxidant Effect in a Mouse Model of Type 2 Diabetes. Diabetes, 2012, 61, 2114-2125.	0.6	32

#	Article	IF	CITATIONS
37	Hyperglycemia and Renal Mass Ablation Synergistically Augment Albuminuria in the Diabetic Subtotally Nephrectomized Rat: Implications for Modeling Diabetic Nephropathy. Nephron Extra, 2012, 2, 115-124.	1.1	4
38	The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2012, 28, 270-287.	1.7	173
39	Bone Marrow Cell Therapies for Endothelial Repair and Their Relevance to Kidney Disease. Seminars in Nephrology, 2012, 32, 215-223.	1.6	11
40	Cell Therapy for Diabetic Nephropathy: Is the Future, Now?. Seminars in Nephrology, 2012, 32, 486-493.	1.6	4
41	FT011, a new antiâ€fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy. European Journal of Heart Failure, 2012, 14, 549-562.	7.1	36
42	Vasoactive Molecules and the Kidney. , 2012, , 384-420.		2
43	The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin–associated hemolytic uremic syndrome in humans and mice. Journal of Clinical Investigation, 2012, 122, 759-776.	8.2	86
44	A Purpose-Synthesised Anti-Fibrotic Agent Attenuates Experimental Kidney Diseases in the Rat. PLoS ONE, 2012, 7, e47160.	2.5	37
45	Hypertension revisited. Canadian Family Physician, 2012, 58, 634-6.	0.4	0
46	Long-Term Administration of the Histone Deacetylase Inhibitor Vorinostat Attenuates Renal Injury in Experimental Diabetes through an Endothelial Nitric Oxide Synthase-Dependent Mechanism. American Journal of Pathology, 2011, 178, 2205-2214.	3.8	134
47	The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2011, 27, 415-433.e2.	1.7	127
48	The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy. Journal of Hypertension, 2011, 29, 1175-1184.	0.5	37
49	Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. Nephrology, 2011, 16, 573-581.	1.6	54
50	Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor. Kidney International, 2011, 79, 1312-1321.	5.2	102
51	Fluorescent Microangiography Is a Novel and Widely Applicable Technique for Delineating the Renal Microvasculature. PLoS ONE, 2011, 6, e24695.	2.5	29
52	Hypertension in people with type 2 diabetes: Update on pharmacologic management. Canadian Family Physician, 2011, 57, 997-1002, e347-53.	0.4	37
53	Culture-Modified Bone Marrow Cells Attenuate Cardiac and Renal Injury in a Chronic Kidney Disease Rat Model via a Novel Antifibrotic Mechanism. PLoS ONE, 2010, 5, e9543.	2.5	55
54	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. Canadian Journal of Cardiology, 2010, 26, 249-258.	1.7	191

#	Article	IF	CITATIONS
55	Expression, Localization, and Function of the Thioredoxin System in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2009, 20, 730-741.	6.1	96
56	Protein kinase C-Â inhibition attenuates the progression of nephropathy in non-diabetic kidney disease. Nephrology Dialysis Transplantation, 2009, 24, 1782-1790.	0.7	21
57	The (Pro)Renin Receptor. Hypertension, 2009, 54, 261-269.	2.7	234
58	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. Canadian Journal of Cardiology, 2009, 25, 287-298.	1.7	111
59	Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H2860-H2869.	3.2	54
60	Macrophage Infiltration and Cellular Proliferation in the Non-Ischemic Kidney and Heart following Prolonged Unilateral Renal Ischemia. Nephron Physiology, 2007, 106, p54-p62.	1.2	47
61	Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14448-14453.	7.1	137
62	High Glucose-Induced Thioredoxin-Interacting Protein in Renal Proximal Tubule Cells Is Independent of Transforming Growth Factor-β1. American Journal of Pathology, 2007, 171, 744-754.	3.8	71
63	Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 193-208.	4.5	58
64	SB-267268, a Nonpeptidic Antagonist of αvβ3and αvβ5Integrins, Reduces Angiogenesis and VEGF Expression i a Mouse Model of Retinopathy of Prematurity. , 2006, 47, 1600.	า	53
65	Transforming Growth Factor-Î ² in Human Diabetic Nephropathy. Diabetes Care, 2006, 29, 2670-2675.	8.6	50
66	Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-?. Cardiovascular Research, 2005, 65, 694-701.	3.8	102
67	Protein Kinase CÎ ² Inhibition Attenuates Osteopontin Expression, Macrophage Recruitment, and Tubulointerstitial Injury in Advanced Experimental Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2005, 16, 1654-1660.	6.1	84
68	Fas-induced apoptosis is a feature of progressive diabetic nephropathy in transgenic (mRen-2)27 rats: Attenuation with renin-angiotensin blockade. Nephrology, 2004, 9, 7-13.	1.6	24
69	Inhibition of Platelet-Derived Growth Factor Promotes Pericyte Loss and Angiogenesis in Ischemic Retinopathy. American Journal of Pathology, 2004, 164, 1263-1273.	3.8	108
70	Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease. Current Opinion in Investigational Drugs, 2004, 5, 276-82.	2.3	10
71	Mast cell infiltration and chemokine expression in progressive renal disease1. Kidney International, 2003, 64, 906-913.	5.2	69
72	Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. American Heart Journal, 2003, 146, 848-853.	2.7	170

#	Article	IF	CITATIONS
73	The Renin-Angiotensin System Influences Ocular Endothelial Cell Proliferation in Diabetes. American Journal of Pathology, 2003, 162, 151-160.	3.8	100
74	Demographics and concomitant disorders in heart failure. Lancet, The, 2003, 362, 147-158.	13.7	127
75	Urinary Connective Tissue Growth Factor Excretion in Patients With Type 1 Diabetes and Nephropathy. Diabetes Care, 2003, 26, 2632-2636.	8.6	103
76	Direct Actions of Urotensin II on the Heart. Circulation Research, 2003, 93, 246-253.	4.5	196
77	COX-2 Inhibition and Retinal Angiogenesis in a Mouse Model of Retinopathy of Prematurity. , 2003, 44, 974.		98
78	Protein Kinase C β Inhibition Attenuates the Progression of Experimental Diabetic Nephropathy in the Presence of Continued Hypertension. Diabetes, 2003, 52, 512-518.	0.6	173
79	Vascular endothelial growth factor expression and glomerular endothelial cell loss in the remnant kidney model. Nephrology Dialysis Transplantation, 2003, 18, 1286-1292.	0.7	35
80	Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney International, 2002, 61, 31-39.	5.2	76
81	Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. Journal of Hepatology, 2001, 35, 376-385.	3.7	159
82	Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney International, 2001, 60, 715-721.	5.2	75
83	Angiotensin-converting enzyme inhibition attenuates renal platelet-derived growth factor gene expression and cell proliferation in subtotal nephrectomy. Nephrology, 2001, 6, 290-297.	1.6	Ο
84	The Interaction between the Renin-Angiotensin System and Vascular Endothelial Growth Factor in the Pathogenesis of Retinal Neovascularization in Diabetes. Journal of Vascular Research, 2001, 38, 527-535.	1.4	26
85	Urinary transforming growth factorâ€Î² in patients with diabetic nephropathy: implications for the pathogenesis of tubulointerstitial pathology. Nephrology Dialysis Transplantation, 2001, 16, 2442-2443.	0.7	17
86	Aminoguanidine Ameliorates Overexpression of Prosclerotic Growth Factors and Collagen Deposition in Experimental Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2001, 12, 2098-2107.	6.1	108
87	Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. Kidney International, 2000, 57, 1882-1894.	5.2	96
88	Osteopontin expression in progressive renal injury in remnant kidney: Role of angiotensin II. Kidney International, 2000, 58, 1469-1480.	5.2	81
89	Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney International, 2000, 58, 2437-2451.	5.2	120
90	ls there a role for endothelin antagonists in diabetic renal disease?. Diabetes, Obesity and Metabolism, 2000, 2, 15-24.	4.4	15

#	Article	IF	CITATIONS
91	Retinal Neovascularization Is Prevented by Blockade of the Renin-Angiotensin System. Hypertension, 2000, 36, 1099-1104.	2.7	216
92	Blockade of the Renin-Angiotensin and Endothelin Systems on Progressive Renal Injury. Hypertension, 2000, 36, 561-568.	2.7	93
93	Endothelin Receptor Antagonism Ameliorates Mast Cell Infiltration, Vascular Hypertrophy, and Epidermal Growth Factor Expression in Experimental Diabetes. Circulation Research, 2000, 86, 158-165.	4.5	72
94	Diabetes-Induced Vascular Hypertrophy Is Accompanied by Activation of Na ⁺ -H ⁺ Exchange and Prevented by Na ⁺ -H ⁺ Exchange Inhibition. Circulation Research, 2000, 87, 1133-1140.	4.5	63
95	Protective role for Epidermal Growth Factor in Advanced Diabetic Nephropathy of Transgenic (mRenâ€2)27 rats. Nephrology, 2000, 5, A102-A102.	1.6	0
96	Protective role for Epidermal Growth Factor in Advanced Diabetic Nephropathy of Transgenic (mRenâ€2)27 rats. Nephrology, 2000, 5, A102-A102.	1.6	0
97	The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury?. Kidney International, 1999, 56, 1627-1637.	5.2	566
98	Role of hyperlipidemia in progressive renal disease: Focus on diabetic nephropathy. Kidney International, 1999, 56, S31-S36.	5.2	79
99	Pathological Expression of Renin and Angiotensin II in the Renal Tubule after Subtotal Nephrectomy. American Journal of Pathology, 1999, 155, 429-440.	3.8	132
100	Renal expression of transforming growth factor-β inducible gene-h3 (βig-h3) in normal and diabetic rats. Kidney International, 1998, 54, 1052-1062.	5.2	79
101	Pathophysiology of diabetic nephropathy. Metabolism: Clinical and Experimental, 1998, 47, 3-6.	3.4	46
102	Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: Morphological and molecular biological studies. Metabolism: Clinical and Experimental, 1998, 47, 24-27.	3.4	16
103	DIABETIC VASCULAR COMPLICATIONS Clinical and Experimental Pharmacology and Physiology, 1997, 24, 770-775.	1.9	54
104	Transforming growth factor \hat{l}^21 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system. Kidney International, 1997, 51, 1553-1567.	5.2	192
105	SPARC gene expression is reduced in early diabetes-related kidney growth. Kidney International, 1995, 48, 1216-1225.	5.2	35
106	Diabetes and Hypertension: Prognostic and Therapeutic Considerations. Blood Pressure, 1995, 4, 329-338.	1.5	8
107	Long-term glycemic control and the rate of progression of early diabetic kidney disease. Kidney International, 1993, 44, 855-859.	5.2	89